Our firm is evaluating testosterone lawsuits on behalf of men who allegedly suffered heart attacks, strokes, deep vein thrombosis, pulmonary embolism and other serious cardiovascular problems as a result of certain hormone replacement therapies.

More than 220 testosterone lawsuits have now been filed in the U.S. District Court, Northern District of Illinois, where cases involving a number of prescription hormone therapies have been centralized in a federal multi district litigation.
A Case List updated on October 15th shows 223 claims now pending in the Northern District of Illinois on behalf of individuals who allegedly suffered strokes, heart attacks, deep vein thrombosis, pulmonary embolism and other serious cardiovascular problems as a result of AndroGel, Testim, Axiron and other prescription therapies. According to claims, the makers of these products failed to adequately warn about their alleged side effects, which may be life-threatening. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

According to court records, testosterone lawsuits now filed in the Northern District of Illinois similarly accuse the drug manufacturers of concealing vital safety information about their products from the public. Plaintiffs further allege that the makers of AndroGel and other medications marketed them for age-related “Low T,” a condition that manifests in low libido, sexual dysfunction, fatigue and other common symptoms of aging. These uses are considered off-label, as prescription testosterone therapies are right now only approved by the U.S. Food and Drug Administration (FDA) to treat men with hypogonadism, or abnormally-low levels of the hormone, caused by an underlying medical condition. By promoting testosterone treatments for uses not approved by the FDA, thousands of men may have been unknowingly placed at risk for serious cardiovascular injuries, plaintiffs further allege.

The litigation involving AndroGel and other widely-used hormone therapies has been increasing steadily since January 2014, when the FDA noted the findings of research that showed an increased heart attack risk in men older than 65 and younger men with a pre-existing history of heart disease. That September, a panel of FDA advisors voted 20-1 to adjust labeling on testosterone products so that they clearly state the lack of evidence proving their safety and efficacy in treating low libido and other aging symptoms. Manufacturers of AndroGel and other medications should also be required to conduct safety studies of their alleged cardiovascular side effects.

Men who suffered heart attacks, strokes, or other cardiovascular problems allegedly related to a testosterone treatment may be entitled to compensation for medical bills, lost wages, pain and suffering and more. For questions about product liability for Low T (testosterone) drugs Click here to contact us for a confidential case review.